ArticleNature nanotechnology2026
Cell-free immuno-profiling on a genetically programmed biochip.
Article in Nature nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tardigrade-Derived Strategy for Low-Cost Storage of Cell-Free Expression Lysates.ACS synthetic biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cell-free synthetic biology approaches offer biosafe, low-cost and versatile genetic tools to advance therapeutic research and development. Measuring the antibody response to a range of target and off-target proteins is essential for deep immuno-profiling of therapeutic antibodies and individual patient immune responses. Here we extend a previously developed microfluidic-free biochip platform to quantitatively reconstitute interactions of cell-free synthesized antigens with antibodies in miniaturized, photolithographically patterned compartments from localized gene brushes. This creates a continuous density gradient of antigens displayed on the surface, generating multiple antibody binding curves, one in each single nanolitre-volume compartment for affinity determination. We used SARS-CoV-2 antigens to profile the specificity and affinity of monoclonal antibodies to more than 30 viral epitopes, which were synthesized simultaneously on a single chip. We also profiled polyclonal antibodies in a total of 1 μl of human serum, revealing patient-specific epitope profiles that are difficult to detect by conventional approaches. By spatially separating gene brushes in the compartment, we extended the gradient approach to reconstitute the interaction of on-chip cell-free expressed human ACE2 receptor with the viral receptor-binding domain in a specific manner. This on-chip genetically programmed approach enables rapid and quantitative interrogation of complex protein-protein interactions, without protein purification steps, for human immuno-profiling and preparedness for emerging pathogens.
Indexed as
Identifiers
41372446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.